Showing results (41-50 of 85) with videos related to
Sort By:
Pageof 9
Plos One|July 7, 2015
Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational StudyEmmanuelle Leray, Sandra Vukusic, Marc Debouverie, et al.Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2021
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With NatalizumabNicolás Fissolo, Beatrice Pignolet, Jordi Rio, et al.CNS Drugs|May 30, 2018
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled StudyAyman Tourbah, Olivier Gout, Alain Vighetto, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2024
Association between education level and disability progression in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.Parkinsonism & Related Disorders|May 4, 2019
Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?Louise-Laure Mariani, Mohamed Doulazmi, Véronique Chaigneau, et al.Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in FranceMathilde Lefort, Olivier Dejardin, Eric Berger, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2020
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MSMikael Cohen, Lydiane Mondot, Florence Bucciarelli, et al.Journal of the Neurological Sciences|March 23, 2016
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled studyLaure Peyro Saint Paul, Christian Creveuil, Olivier Heinzlef, et al.Neurology and Therapy|February 10, 2023
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French CohortJuliette Pelle, Anais R Briant, Pierre Branger, et al.Pageof 9